Patent Yard Sign in
Expired Canadian patentCanada

2-alkoxy-n-(1-azabicyclo2.2.2 oct-3-yl) benzamides and thiobenzamides in amethod for alleviating emesis caused by non-platinum anticancer drugs

CA 1284953 C · Owner: Boswell, Robert F. · Inventors: Munson, Harry R. Jr.; Boswell, Robert F.; Smith, William L.

CIPO record

Overview

Drawings and full text

Its claims, description and drawings are in the Canadian Patents Database.

Open the CIPO record

Abstract From the Canadian patent

2-ALKOXY-N-(1-AZABICYCLO2.2.2OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES IN A, METHOD FOR ALLEVIATING EMESIS CAUSED BY NON-PLATINUM ANTICANCER DRUGS, ABSTRACT OF THE INVENTION A composition for alleviating emesis caused by non-platinum anti-cancer drugs with 2-alkoxy-N-(1-azabicyclo2.2.2oct- 3-yl)benzamides and thiobenzamides having the formula wherein X is oxygen or sulfur; R1 is loweralkyl; and R2 is selected from the group consisting of hydrogen halo, 4,5-benzo, methylsulfonyl, loweralkoxy or Am and n is 1 or 2, and the pharmaceutically acceptable acid addition salts thereof is disclosed.

Read the whole patent

Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.

Why it's free to use

  • Granted June 18, 1991. A Canadian patent filed before October 1, 1989 lasted 17 years from grant, so its term ended June 18, 2008.
  • We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
FiledMarch 4, 1987
GrantedJune 18, 1991
Term endedJune 18, 2008
Patent numberCA 1284953 C
Classification (IPC)A61K31/43 +2 more

Timeline

Timeline From CIPO dates

1988199119941997200020032006Application filedMarch 4, 1987Patent grantedJune 18, 1991Term endedJune 18, 2008

Sources & verification

Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.